Drug interactions
Aprepitant + Larotrectinib
Severity: Minor
Aprepitant and Larotrectinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a CYP3A4 substrate with possible weak inhibitory effects, so the effect on aprepitant is likely small. Any rise in aprepitant levels would be modest.
What this interaction means in plain words
Aprepitant and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Aprepitant belongs to Gastrointestinal Tract; Larotrectinib belongs to Oncology.
Why it happens
Possible weak CYP3A4 inhibition by larotrectinib reducing aprepitant clearance.
What to do
No dose adjustment is needed; monitor for aprepitant adverse effects. Larotrectinib levels may also rise with aprepitant, so monitor its toxicity.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Aprepitant and Larotrectinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Aprepitant
- Aprepitant + Lomitapide Contraindicated
- Aprepitant + Pimozide Contraindicated
- Aprepitant + Avapritinib Major
- Aprepitant + Bosutinib Major
- Aprepitant + Carbamazepine Major
- Aprepitant + Cobicistat Major
Other interactions of Larotrectinib
Frequently asked questions
Can I take Aprepitant with Larotrectinib?
MediHelp rates the interaction as minor. Aprepitant and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a CYP3A4 substrate with possible weak inhibitory effects, so the effect on aprepitant is likely small. Any rise in aprepitant levels would be modest.
How serious is the interaction between Aprepitant and Larotrectinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is needed; monitor for aprepitant adverse effects. Larotrectinib levels may also rise with aprepitant, so monitor its toxicity.
What other medicines interact with Aprepitant?
MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
